Venus Remedies Limited has informed the Exchange regarding Board meeting held on August 01, 2025.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venus Remedies reported strong Q1 FY26 results, with consolidated revenue from operations rising to ₹131.90 Cr from ₹108.61 Cr in Q1 FY25, a growth of about 21%. Consolidated net profit jumped sharply to ₹9.60 Cr from just ₹1.22 Cr a year ago, while EBITDA grew to ₹18.80 Cr. On a standalone basis, revenue climbed to ₹131.85 Cr (vs ₹105.86 Cr) and net profit rose to ₹11.69 Cr (vs ₹4.45 Cr), with EPS of ₹8.76. The auditor flagged two emphasis-of-matter points: German subsidiary Venus Pharma GmbH's net worth has turned negative by ₹295.40 lakhs, raising a going-concern doubt, and ₹2,859.72 lakhs of share application money for that subsidiary remains pending allotment due to German law requirements.
Strong quarterly performance with double-digit revenue growth and a near 7x jump in consolidated net profit is positive for shareholders. However, the auditor's emphasis on the German subsidiary's negative net worth and large unrecovered share application money represents a real risk overhang on the stock.